SCHEMBL7686447

SCHEMBL7686447

COc1ccc(S(=O)(=O)N2CCN(C(=O)OC(C)(C)C)C[C@H]2C(=O)O)cc1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 4/20 0.60
MMP9 P14780 3/20 0.60
MMP3 P08254 2/20 0.60
MMP7 P09237 2/20 0.60
MMP13 P45452 4/20 0.53
MAPT P10636 1/20 0.49
HCRTR1 O43613 2/20 0.48
HCRTR2 O43614 2/20 0.48
PDE4B Q07343 3/20 0.46
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 1/20 0.45
TSHR P16473 1/20 0.44
STS P08842 1/20 0.44
GPBAR1 Q8TDU6 1/20 0.44
MEN1 O00255 1/20 0.43
ADAM17 P78536 2/20 0.43
LMNA P02545 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7685520 1.00 MMP1 (0.60) MMP1MMP9MMP3MMP7MMP13
SCHEMBL7690350 0.85 MMP1 (0.54) MMP1MMP9MMP3MMP7MMP13
SCHEMBL12659053 0.84 MMP1 (0.62) MMP1MMP9MMP3MMP7MMP13
SCHEMBL4035557 0.83 MMP1 (0.62) MMP1MMP9MMP3MMP7MMP13
SCHEMBL4037002 0.83 MMP1 (0.62) MMP1MMP9MMP3MMP7MMP13
SCHEMBL4038681 0.83 MMP1 (0.62) MMP1MMP9MMP3MMP7MMP13
SCHEMBL2441360 0.83 MMP1 (0.64) MMP1MMP9MMP3MMP7MMP13
SCHEMBL7687390 0.82 MMP1 (0.64) MMP1MMP9MMP3MMP7MMP13
SCHEMBL4036361 0.82 MMP9 (0.60) MMP1MMP9MMP3MMP7MMP13
SCHEMBL4038253 0.82 MMP9 (0.60) MMP1MMP9MMP3MMP7MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020128269-A1 Substituted heterocyclic compounds for treating multidrug resistance PROCTER & GAMBLE COMPANY, THE 2002-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128269-A1 Substituted heterocyclic compounds for treating multidrug resistance ABCC1, ABCB1, ABCG2 MMP1 3802/4885MMP9 2228/4885MMP3 2583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.